Literature DB >> 21078401

Synthesis, characterization, and monkey positron emission tomography (PET) studies of [18F]Y1-973, a PET tracer for the neuropeptide Y Y1 receptor.

Eric D Hostetler1, Sandra Sanabria-Bohórquez, Hong Fan, Zhizhen Zeng, Liza Gantert, Mangay Williams, Patricia Miller, Stacey O'Malley, Minoru Kameda, Makoto Ando, Nagaaki Sato, Satoshi Ozaki, Shigeru Tokita, Hisashi Ohta, David Williams, Cyrille Sur, Jacquelynn J Cook, H Donald Burns, Richard Hargreaves.   

Abstract

Neuropeptide Y receptor subtype 1 (NPY Y1) has been implicated in appetite regulation, and antagonists of NPY Y1 are being explored as potential therapeutics for obesity. An NPY Y1 PET tracer is useful for determining the level of target engagement by NPY Y1 antagonists in preclinical and clinical studies. Here we report the synthesis and evaluation of [(18)F]Y1-973, a novel PET tracer for NPY Y1. [(18)F]Y1-973 was radiolabeled by reaction of a primary chloride with [(18)F]KF/K2.2.2 followed by deprotection with HCl. [(18)F]Y1-973 was produced with high radiochemical purity (>98%) and high specific activity (>1000 Ci/mmol). PET studies in rhesus monkey brain showed that the distribution of [(18)F]Y1-973 was consistent with the known NPY Y1 distribution; uptake was highest in the striatum and cortical regions and lowest in the pons, cerebellum nuclei, and brain stem. Blockade of [(18)F]Y1-973 uptake with NPY Y1 antagonist Y1-718 revealed a specific signal that was dose-dependently reduced in all regions of grey matter to a similarly low level of tracer uptake, indicative of an NPY Y1 specific signal. In vitro autoradiographic studies with [(18)F]Y1-973 in rhesus monkey and human brain tissue slices revealed an uptake distribution consistent with the in vivo PET studies. Highest binding density was observed in the dentate gyrus, caudate-putamen, and cortical regions; moderate binding density in the hypothalamus and thalamus; and lowest binding density in the globus pallidus and cerebellum. In vitro saturation binding studies in rhesus monkey and human caudate-putamen homogenates confirmed a similarly high B(max)/K(d) ratio for [(18)F]Y1-973, suggesting the tracer may provide a specific signal in human brain of similar magnitude to that observed in rhesus monkey. [(18)F]Y1-973 is a suitable PET tracer for imaging NPY Y1 in rhesus monkey with potential for translation to human PET studies.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21078401     DOI: 10.1016/j.neuroimage.2010.11.014

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  12 in total

Review 1.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

2.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 3.  Neuropeptide Y and posttraumatic stress disorder.

Authors:  R Sah; T D Geracioti
Journal:  Mol Psychiatry       Date:  2012-07-17       Impact factor: 15.992

Review 4.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

5.  Postprandial plasma PYY concentrations are associated with increased regional gray matter volume and rCBF declines in caudate nuclei--a combined MRI and H2(15)O PET study.

Authors:  Christopher M Weise; Pradeep Thiyyagura; Eric M Reiman; Kewei Chen; Jonathan Krakoff
Journal:  Neuroimage       Date:  2011-12-21       Impact factor: 6.556

6.  Prototypic 18F-Labeled Argininamide-Type Neuropeptide Y Y1R Antagonists as Tracers for PET Imaging of Mammary Carcinoma.

Authors:  Max Keller; Simone Maschauer; Albert Brennauer; Philipp Tripal; Norman Koglin; Ralf Dittrich; Günther Bernhardt; Torsten Kuwert; Hans-Jürgen Wester; Armin Buschauer; Olaf Prante
Journal:  ACS Med Chem Lett       Date:  2017-02-21       Impact factor: 4.345

Review 7.  PET Imaging of the Neuropeptide Y System: A Systematic Review.

Authors:  Inês C F Fonseca; Miguel Castelo-Branco; Cláudia Cavadas; Antero J Abrunhosa
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

8.  Neuropeptide Y receptor gene expression in the primate amygdala predicts anxious temperament and brain metabolism.

Authors:  Patrick H Roseboom; Steven A Nanda; Andrew S Fox; Jonathan A Oler; Alexander J Shackman; Steven E Shelton; Richard J Davidson; Ned H Kalin
Journal:  Biol Psychiatry       Date:  2013-11-15       Impact factor: 13.382

Review 9.  Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity.

Authors:  C K Boughton; K G Murphy
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 10.  Relaxin' the brain: a case for targeting the nucleus incertus network and relaxin-3/RXFP3 system in neuropsychiatric disorders.

Authors:  Jigna Rajesh Kumar; Ramamoorthy Rajkumar; Tharindunee Jayakody; Subhi Marwari; Jia Mei Hong; Sherie Ma; Andrew L Gundlach; Mitchell K P Lai; Gavin S Dawe
Journal:  Br J Pharmacol       Date:  2016-09-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.